Versartis, Inc. (VSAR) Receives Average Recommendation of “Hold” from Analysts

Versartis, Inc. (NASDAQ:VSAR) has earned an average recommendation of “Hold” from the twelve analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $5.63.

Several research analysts have recently commented on VSAR shares. Morgan Stanley reissued an “equal weight” rating and issued a $4.00 target price (up from $3.00) on shares of Versartis in a report on Friday, September 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $14.00 target price (down from $34.00) on shares of Versartis in a report on Friday, September 22nd. Cowen downgraded Versartis from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $45.00 to $3.00 in a report on Friday, September 22nd. Bank of America downgraded Versartis from a “buy” rating to a “neutral” rating in a report on Monday, September 25th. Finally, ValuEngine downgraded Versartis from a “sell” rating to a “strong sell” rating in a report on Friday, September 22nd.

Versartis (VSAR) opened at $2.28 on Monday. The company has a market capitalization of $81.47, a P/E ratio of -0.58 and a beta of 2.36. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.11. Versartis has a 1-year low of $1.60 and a 1-year high of $24.00.

Versartis (NASDAQ:VSAR) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.78). During the same period last year, the business earned ($0.92) earnings per share. research analysts anticipate that Versartis will post -4.14 earnings per share for the current fiscal year.

In other news, Director Srinivas Akkaraju acquired 513,872 shares of Versartis stock in a transaction on Monday, December 4th. The shares were purchased at an average price of $2.21 per share, with a total value of $1,135,657.12. Following the acquisition, the director now owns 14,955 shares in the company, valued at $33,050.55. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last ninety days, insiders have sold 2,769 shares of company stock worth $7,061. Company insiders own 10.90% of the company’s stock.

Several hedge funds have recently bought and sold shares of VSAR. Schwab Charles Investment Management Inc. lifted its stake in shares of Versartis by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 109,409 shares of the biopharmaceutical company’s stock valued at $1,910,000 after purchasing an additional 627 shares during the period. Rhumbline Advisers lifted its stake in shares of Versartis by 4.2% in the 2nd quarter. Rhumbline Advisers now owns 35,388 shares of the biopharmaceutical company’s stock valued at $618,000 after purchasing an additional 1,420 shares during the period. State of Wisconsin Investment Board acquired a new position in shares of Versartis in the 2nd quarter valued at $419,000. Marshall Wace North America L.P. acquired a new position in shares of Versartis in the 2nd quarter valued at $495,000. Finally, Prudential Financial Inc. acquired a new position in shares of Versartis in the 2nd quarter valued at $469,000. 49.18% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Versartis, Inc. (VSAR) Receives Average Recommendation of “Hold” from Analysts” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/08/versartis-inc-vsar-receives-average-recommendation-of-hold-from-analysts.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Analyst Recommendations for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply